



PAVING THE WAY TO NOVEL THERAPIES IN CLL

Real World Patient Cases for
the Oncology Pharmacist

Permissions

Slide 8: Reprinted by permission from Springer Nature: *Nat Rev Clin Oncol*; Burger JA, O'Brien S. Evolution of CLL treatment—from chemoimmunotherapy to targeted and individualized therapy; 15(8):510–527. Copyright © 2018.

Slide 13: From *New England Journal of Medicine*; Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CL; 379(26):2517–2528. Copyright ©2018 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.

Slide 15: From *New England Journal of Medicine*; Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions; 380(23):2225–2236. Copyright ©2019 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.

Slide 15: Reprinted by permission from Elsevier: *Lancet Oncology*; Al-Sawaf O, et al. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial; volume 21(9): pages 1188–1200. Copyright © 2020.

Slide 22: Copyright © Kevin Kuo, MD, MHPE. Used with permission. All rights reserved.

Slide 25: From *Am J Hematol*: Munir T, Brown JR, O'Brien S, et al. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma; 94(12):1353–1363. Copyright © 2019 The Authors. *American Journal of Hematology* published by Wiley Periodicals, Inc. License available at <https://creativecommons.org/licenses/by-nc/4.0/legalcode>. Accessed October 2021.

Slide 28: Kater AP, Seymour JF, Hillmen P, et al. Fixed duration of venetoclax-rituximab in relapsed/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the murano phase III study. *J Clin Oncol*. 2019;37(4):269–277. Reprinted with permission. © 2019 American Society of Clinical Oncology. All rights reserved.

Slide 37: From *Blood*: Barr PM, et al. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL;129(19):2612–2615. Copyright © 2017 by the American Society of Hematology.

Slide 38: From *J Pharmacol Exp Ther: Leukemia*: Barf T, Covey T, Izumi R, et al. Acalabrutinib (ACP-196): a covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile; 363(2):240–252. Copyright © 2017. License available at <https://creativecommons.org/licenses/by-nc/4.0/legalcode>. Accessed October 2021.